For the fifth year, the Nordic Star Awards was presented at the end of the NLSDays conference, honoring three innovative life science companies in the Nordic region.
Nordic Stars Awards were introduced in 2013 in special recognition of life science companies in the Nordic region demonstrating outstanding innovation and entrepreneurial skills. And the lucky winners this year were Herantis Pharma, Pelago Bioscience and Targovax. The awards were presented at the conclusion of the Nordic Life Science Days in Malmö, which also set a new record for attendance. Over 1,300 delegates representing more than 800 companies from 40 countries joined the conference.
3 000 face to face meetings took place during this years event, commented Olivier Duchamp and Björn Ursing from SwedenBIO gave the audience a flavor of next year’s event: Reproductive medicine, nanomedicine, oncology were some of the topics.
Björn Ursing, Chairman of the Nordic Stars Award commented: “At SwedenBIO we are proud to present the three winners of the Nordic Stars Awards 2017. Each of them has demonstrated impressive entrepreneurial spirit, combined with a passion for developing innovative solutions for their respective clients or patient groups. Together, they are all excellent examples of how Nordic companies can contribute to better healthcare globally.”
The 2017 Nordic Stars:
Herantis pharma follows a truly patient centric approach, addressing major unmet medical needs with a broad product portfolio in various therapeutic areas. They have several projects in clinical phase already showing promising results. Their basis in academia has also paved the way for extensive scientific collaborations.
Pelago Bioscience provides a unique model for in situ target engagement studies. The company shows that a well-run service provider with a breakthrough technology can play a key role in developing more efficient processes for both preclinical and clinical drug development. With its partners, it shows true collaborative spirit.
Targovax has two clinical-stage immune-oncology projects with different approaches for solid tumors. Recently having secured a large private placement, Targovax now has the resources required to run the therapies in both stand-alone and combination trials.
Photo: Anniki Skeidsvoll Edén